FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Aisen

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Procedures

Physiology

Disease Progression

Concepts & Ideas

Living Beings

Co-author Network

Publications

TOP 3
Paul S Aisen; Bruno Vellas; Harald Hampel
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.
Robert A Rissman; Leslie M Shaw; John Q Trojanowski; Paul S Aisen
Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease.
Rahul S Desikan; Dominic Holland; Linda K McEvoy; Reisa A Sperling; Wesley K Thompson; Paul S Aisen; James B Brewer; Anders M Dale
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Aisen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paul S Aisen; Bruno Vellas; Harald Hampel
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.
Nature reviews. Drug discovery 2013;12(4):324.
2012: Robert A Rissman; Leslie M Shaw; John Q Trojanowski; Paul S Aisen
Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2012;119(7):843-50.
2012: Rahul S Desikan; Dominic Holland; Linda K McEvoy; Reisa A Sperling; Wesley K Thompson; Paul S Aisen; James B Brewer; Anders M Dale
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.
Archives of neurology 2012;69(6):709-13.
2012: M C Donohue; Paul S Aisen
Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials.
The journal of nutrition, health & aging 2012;16(4):360-4.
2012: R Scott Mackin; Michael W Weiner; Paul S Aisen; Yonas E Geda; Philip Insel
Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years.
International journal of geriatric psychiatry 2012;27(4):355-63.
2012: Paul S Aisen; Jeffrey Cummings; Lon S Schneider
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Cold Spring Harbor perspectives in medicine 2012;2(3):a006395.
2012: Michael W Weiner; Paul S Aisen; Laurel Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William J Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J. Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski; Dallas P Veitch
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2012;8(1 Suppl):S1-68.
2012: Rochelle E Tractenberg; Futoshi Yumoto; Paul S Aisen; Jeffrey A Kaye; Robert J Mislevy
Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost".
PloS one 2012;7(2):e30019.
2011: Paul S Aisen
Clinical trial methodologies for disease-modifying therapeutic approaches.
Neurobiology of aging 2011;32 Suppl 1():S64-6.
2011: Rahul S Desikan; Dominic Holland; Bradley T Hyman; Linda K McEvoy; J Cooper Roddey; Wesley K Thompson; Paul S Aisen; Kaj Blennow; James B Brewer; Anders M Dale
Amyloid-β associated volume loss occurs only in the presence of phospho-tau.
Annals of neurology 2011;70(4):657-61.
2011: Jon B Toledo; John Q Trojanowski; hugo vanderstichele; Michael W Weiner; Sharon X Xie; Paul S Aisen; Charles DeCarli; Michal Figurski; Clifford R Jack; William Jagust; Virginia M-Y Lee; Ronald C. Petersen; Leslie M Shaw; Arthur W Toga; Estefanía Toledo
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.
Acta neuropathologica 2011;122(4):401-13.
2011: Gloria C Chiang; Nick C Fox; Anthony Gamst; Danielle Harvey; Philip S Insel; Clifford R Jack; William J Jagust; Ronald C. Petersen; Sky T Raptentsetsang; Eric Reiman; Norbert Schuff; Paul M Thompson; Duygu Tosun; Diana Truran-Sacrey; Michael W Weiner; Paul S Aisen; Laurel Beckett
Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2011;7(5):514-20.
2011: Marwan N Sabbagh; Edward Schweizer; Albert Agro; Paul S Aisen; Joanne Bell; Douglas Galasko
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.
Alzheimer disease and associated disorders 2011;25(3):206-12.
2011: M S Rafii; S Walsh; John Timothy Little; K Behan; B Reynolds; C Ward; S Jin; R Thomas; Paul S Aisen
A phase II trial of huperzine A in mild to moderate Alzheimer disease.
Neurology 2011;76(16):1389-94.
2011: Michael C Donohue; Anthony Gamst; Paul S Aisen
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2011;7(2):245-6; author reply 247-9.
2011: Paul S Aisen; Anh Duong; Steven H Ferris; Denis Garceau; S Gauthier; Denis Haine; Wan C Lau; Joonmi Oh; Daniel Saumier; Joyce Suhy; John Sampalis
Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).
Archives of medical science : AMS 2011;7(1):102-11.
2011: Takako Niikura; Elkhansa Sidahmed; Chiho Hirata-Fukae; Paul S Aisen; Yasuji Matsuoka
A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.
PloS one 2011;6(1):e16259.
2010: G C Chiang; P S Insel; Duygu Tosun; Norbert Schuff; D Truran-Sacrey; S T Raptentsetsang; Clifford R Jack; Paul S Aisen; Ronald C. Petersen; Michael Weiner
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects.
Neurology 2010;75(22):1976-81.
2010: Danielle C Whitehair; Abdullah Sherzai; Jennifer Emond; Rema Raman; Paul S Aisen; Ronald C. Petersen; Adam S Fleisher
Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2010;6(5):412-9.
2010: Linda K McEvoy; Steven D Edland; Dominic Holland; Donald J Hagler; J Cooper Roddey; Christine Fennema-Notestine; David P Salmon; Alain K Koyama; Paul S Aisen; James B Brewer; Anders Dale
Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease.
Alzheimer disease and associated disorders 2010;24(3):269-77.
2010: Paul S Aisen; Ronald C. Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel Beckett; Clifford R Jack; William J Jagust; Arthur W Toga; Andrew J. Saykin; John C Morris; Robert C Green; Michael Weiner
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2010;6(3):239-46.
2009: Rema Raman; Ronald Thomas; Michael Weiner; Clifford R Jack; Karin Ernstrom; Paul S Aisen; Pierre N. Tariot; Joseph F Quinn
MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population.
Alzheimer disease and associated disorders 2009;23(4):333-6.
2009: Yasuji Matsuoka; Howard F Andrews; Amanda G Becker; Audrey J Gray; Pankaj D Mehta; Mary Sano; Arthur J Dalton; Paul S Aisen
The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome.
Alzheimer disease and associated disorders 2009;23(4):315-8.
2009: Rochelle E Tractenberg; Paul S Aisen; Gregory R Hancock; G. William Rebeck
No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease.
Neurobiology of aging 2009;30(8):1327-8.
2009: Pierre N. Tariot; Paul S Aisen
Can lithium or valproate untie tangles in Alzheimer's disease?
The Journal of clinical psychiatry 2009;70(6):919-21.
2009: S Gauthier; Paul S Aisen; S H Ferris; D Saumier; A Duong; Denis Haine; D Garceau; J Suhy; J Oh; W Lau; J Sampalis
Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
The journal of nutrition, health & aging 2009;13(6):550-7.
2009: Ralitza Vozdolska; Mary Sano; Paul S Aisen; Steven D Edland
The net effect of alternative allocation ratios on recruitment time and trial cost.
Clinical trials (London, England) 2009;6(2):126-32.
2009: D Saumier; Paul S Aisen; S Gauthier; Bruno Vellas; S H Ferris; A Duong; J Suhy; J Oh; W Lau; D Garceau; Denis Haine; J Sampalis
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.
The journal of nutrition, health & aging 2009;13(4):370-2.
2009: Paul S Aisen
Interpreting biomarker data in therapeutic trials.
The journal of nutrition, health & aging 2009;13(4):337-8.
2009: Leslie M Shaw; hugo vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C. Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Annals of neurology 2009;65(4):403-13.
2009: Paul S Aisen
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2009;5(2):125-7.
2009: ZAVEN KHACHATURIAN; Peter J Snyder; Rachelle S Doody; Paul S Aisen; Meryl Comer; John Dwyer; Richard A Frank; Andrew Holzapfel; Ara Khachaturian; Amos D Korczyn; Allen D Roses; James W Simpkins; Lon S Schneider; Marilyn S Albert; Robert Egge; Aaron Deves; Steven Ferris; Barry D Greenberg; Carl Johnson; Walter A Kukull; Judes Poirier; Dale Schenk; William Thies; S Gauthier; Sid Gilman; Charles Bernick; Jeffrey L Cummings; Howard Fillit; Michael Grundman; Jeffrey A Kaye; Lennart Mucke; Barry Reisberg; Mary Sano; Oxana Pickeral; Ronald C. Petersen; Richard C Mohs; Maria Carrillo; Jody Corey-Bloom; Norman L Foster; Steve Jacobsen; Virginia M-Y Lee; William Z Potter; Marwan Sabbagh; David P Salmon; John Q Trojanowski; Nancy Wexler; Lisa J Bain
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2009;5(2):85-92.
2009: Chiho Hirata-Fukae; Hui-Fang Li; Li Ma; Hyang-Sook Hoe; G. William Rebeck; Paul S Aisen; Yasuji Matsuoka
Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo.
Neuroscience letters 2009;450(1):51-5.
2009: Adam S Fleisher; Michael Donohue; Kewei Chen; James B Brewer; Paul S Aisen
Applications of neuroimaging to disease-modification trials in Alzheimer's disease.
Behavioural neurology 2009;21(1):129-36.
2009: Paul S Aisen
Alzheimer's disease therapeutic research: the path forward.
Alzheimer's research & therapy 2009;1(1):2.
2009: Rochelle E Tractenberg; Paul S Aisen
Agreement in cognitive and clinical assessments in Alzheimer's disease.
Dementia and geriatric cognitive disorders 2009;27(4):344-52.
2009: Michael S Rafii; Paul S Aisen
Recent developments in Alzheimer's disease therapeutics.
BMC medicine 2009;7():7.
2009: Sandrine Andrieu; Nicola Coley; Paul S Aisen; Maria C Carrillo; Steven T DeKosky; Jane Durga; Howard Fillit; Giovanni B Frisoni; Lutz Froelich; S Gauthier; Roy Jones; Linus Jönsson; ZAVEN KHACHATURIAN; John C Morris; Jean-Marc Orgogozo; Pierre-Jean Ousset; Philippe Robert; Eric Salmon; Cristina Sampaio; Frans Verhey; Gordon K Wilcock; Bruno Vellas
Methodological issues in primary prevention trials for neurodegenerative dementia.
Journal of Alzheimer's disease : JAD 2009;16(2):235-70.
2009: Michael C Irizarry; Rema Raman; Michael A Schwarzschild; Lida M Becerra; Ronald G Thomas; Ronald C Peterson; Alberto Ascherio; Paul S Aisen
Plasma urate and progression of mild cognitive impairment.
Neuro-degenerative diseases 2009;6(1-2):23-8.
2008: Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald Thomas; Leon J Thal
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2008;300(15):1774-83.
2008: Paul S Aisen
Amyloid-based therapeutics: findings translated into novel treatments.
CNS spectrums 2008;13(10 Suppl 16):36-8.
2008: Julian R Haigh; Scott R Johnston; Adam Peppernay; Patrick J Mattern; Gregory E Garcia; Bhupendra P Doctor; Richard Gordon; Paul S Aisen
Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase.
Chemico-biological interactions 2008;175(1-3):380-6.
2008: Adam S Fleisher; Rema Raman; Eric R Siemers; Lida Becerra; Christopher M Clark; Robert A Dean; Martin R Farlow; James E Galvin; Elaine Peskind; Joseph F Quinn; Abdullah Sherzai; B Brooke Sowell; Paul S Aisen; Leon J Thal
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.
Archives of neurology 2008;65(8):1031-8.
2008: Rachelle S Doody; Svetlana I Gavrilova; Mary Sano; Ronald Thomas; Paul S Aisen; Sergey O Bachurin; Lynn Seely; David Hung
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
Lancet 2008;372(9634):207-15.
2008: Chiho Hirata-Fukae; Hui-Fang Li; Hyang-Sook Hoe; Audrey J Gray; S Sakura Minami; Katsuyoshi Hamada; Takako Niikura; Fang Hua; Hiroe Tsukagoshi-Nagai; Yuko Horikoshi-Sakuraba; Mohamed Mughal; G. William Rebeck; Frank M LaFerla; Mark P Mattson; Nobuhisa Iwata; Takaomi C Saido; William L Klein; karen duff; Paul S Aisen; Yasuji Matsuoka
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
Brain research 2008;1216():92-103.
2008: Paul S Aisen
Tarenflurbil: a shot on goal.
Lancet neurology 2008;7(6):468-9.
2008: Paul S Aisen
Treatment for MCI: is the evidence sufficient?
Neurology 2008;70(22):2020-1.
2008: ZAVEN KHACHATURIAN; Ronald C. Petersen; S Gauthier; Neil Buckholtz; Jody Corey-Bloom; Bill Evans; Howard Fillit; Norman Foster; Barry Greenberg; Michael Grundman; Mary Sano; James Simpkins; Lon S Schneider; Michael Weiner; Douglas Galasko; Bradley T Hyman; Lew Kuller; Dale Schenk; Stephen Snyder; Ronald Thomas; Mark H Tuszynski; Bruno Vellas; Richard J Wurtman; Peter J Snyder; Richard A Frank; Marilyn S Albert; Rachelle S Doody; Steven H Ferris; Jeffrey A Kaye; Edward H Koo; Marcelle Morrison-Bogorad; Barry Reisberg; David P Salmon; Sid Gilman; Richard C Mohs; Paul S Aisen; John C S Breitner; Jeffrey L Cummings; Claudia Kawas; Creighton Phelps; Judes Poirier; Marwan Sabbagh; Jacques Touchon; Ara Khachaturian; Lisa J Bain
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2008;4(3):156-63.
2008: Chiho Hirata-Fukae; Elkhansa Hassan Sidahmed; Thomas P Gooskens; Paul S Aisen; Ilse Dewachter; Herman Devijver; Fred Van Leuven; Yasuji Matsuoka
Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo.
Neuroscience letters 2008;435(3):186-9.
2008: Yasuji Matsuoka; Yan Jouroukhin; Audrey J Gray; Li Ma; Chiho Hirata-Fukae; Hui-Fang Li; Li Feng; Laurent Lecanu; Benjamin R Walker; Emmanuel Planel; Ottavio Arancio; Illana Gozes; Paul S Aisen
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
The Journal of pharmacology and experimental therapeutics 2008;325(1):146-53.
2008: Paul S Aisen; Leon J Thal; Steven H Ferris; Chris Assaid; Michael L Nessly; Michael J Giuliani; Christopher R Lines; Barbara A Norman; William Z Potter
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.
Current Alzheimer research 2008;5(1):73-82.
2008: John Timothy Little; Sally Walsh; Paul S Aisen
An update on huperzine A as a treatment for Alzheimer's disease.
Expert opinion on investigational drugs 2008;17(2):209-15.
2008: Adam S Fleisher; S Sun; C Taylor; C P Ward; Anthony Gamst; Ronald C. Petersen; Clifford R Jack; Paul S Aisen; Leon J Thal
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
Neurology 2008;70(3):191-9.
2008: Paul S Aisen
Leon Thal and the therapeutic age of Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2008;4(1 Suppl 1):S4-6.
2008: Paul S Aisen
The inflammatory hypothesis of Alzheimer disease: dead or alive?
Alzheimer disease and associated disorders 2008;22(1):4-5.
2008: Paul S Aisen
An aspirin a day for Alzheimer's disease?
Lancet neurology 2008;7(1):20-1.
2007: Kazuyuki Takata; Chiho Hirata-Fukae; Amanda Becker; Saori Chishiro; Audrey J Gray; Kouhei Nishitomi; Andreas H Franz; Gaku Sakaguchi; Akira Kato; Mark P Mattson; Frank M LaFerla; Paul S Aisen; Yoshihisa Kitamura; Yasuji Matsuoka
Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration.
The European journal of neuroscience 2007;26(9):2458-68.
2007: Paul S Aisen
Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006."--an appraisal.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2007;3(4):446-8.
2007: Paul S Aisen; S Gauthier; Bruno Vellas; Richard Briand; Daniel Saumier; Julie Laurin; Denis Garceau
Alzhemed: a potential treatment for Alzheimer's disease.
Current Alzheimer research 2007;4(4):473-8.
2007: Audrey J Gray; Gaku Sakaguchi; Chiharu Shiratori; Amanda Becker; John LaFrancois; Paul S Aisen; karen duff; Yasuji Matsuoka
Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Neuroreport 2007;18(3):293-6.
2007: Rochelle E Tractenberg; Myron Weiner; Paul S Aisen; Jeffrey A Kaye; Jong-Ling Fuh
A simple method to rule out dementia with temporal orientation.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2007;3(1):28-32.
2007: Yasuji Matsuoka; Audrey J Gray; Chiho Hirata-Fukae; S Sakura Minami; Emily Graeme Waterhouse; Mark P Mattson; Frank M LaFerla; Illana Gozes; Paul S Aisen
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
Journal of molecular neuroscience : MN 2007;31(2):165-70.
2006: Kouhei Nishitomi; Gaku Sakaguchi; Yuko Horikoshi; Audrey J Gray; Masahiro Maeda; Chiho Hirata-Fukae; Amanda Becker; Motoko Hosono; Isako Sakaguchi; S Sakura Minami; Yoshihiro Nakajima; Hui-Fang Li; Chie Takeyama; Tsuyoshi Kihara; Akinobu Ota; Philip C Wong; Paul S Aisen; Akira Kato; Noriaki Kinoshita; Yasuji Matsuoka
BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
Journal of neurochemistry 2006;99(6):1555-63.
2006: Paul S Aisen; Daniel Saumier; R Briand; Julie Laurin; Francine Gervais; Patrick Tremblay; Denis Garceau
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Neurology 2006;67(10):1757-63.
2006: Rochelle E Tractenberg; Paul S Aisen; Myron Weiner; Jeffrey L Cummings; Gregory R Hancock
Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2006;2(4):303-13.
2006: Paul S Aisen
Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials".
Alzheimer's & dementia : the journal of the Alzheimer's Association 2006;2(4):272-4.
2006: Sally P Walsh; Rema Raman; Katherine B Jones; Paul S Aisen
ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI).
Alzheimer disease and associated disorders 2006;20(4 Suppl 3):S170-8.
2006: Steven H Ferris; Paul S Aisen; Jeffrey L Cummings; Douglas Galasko; David P Salmon; Lon S Schneider; Mary Sano; Peter J Whitehouse; Steven D Edland; Leon J Thal
ADCS Prevention Instrument Project: overview and initial results.
Alzheimer disease and associated disorders 2006;20(4 Suppl 3):S109-23.
2006: Paul S Aisen
Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2006;2(3):153-4.
2006: L T Loftus; H-F Li; Audrey J Gray; Chiho Hirata-Fukae; Bogdan A Stoica; J Futami; H Yamada; Paul S Aisen; Yasuji Matsuoka
In vivo protein transduction to the CNS.
Neuroscience 2006;139(3):1061-7.
2005: Richard Gordon; Julian R Haigh; Gregory E Garcia; Shawn R Feaster; Michael A Riel; David Lenz; Paul S Aisen; Bhupendra P Doctor
Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
Chemico-biological interactions 2005;157-158():239-46.
2005: Paul S Aisen
Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment?
Nature clinical practice. Neurology 2005;1(1):20-1.
2005: Rochelle E Tractenberg; Paul S Aisen; Yi-Li Chuang
One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline.
American journal of Alzheimer's disease and other dementias 2005;20(4):239-47.
2005: Yasuji Matsuoka; Li Shao; Manik Debnath; John LaFrancois; Amanda Becker; Audrey Gray; Paul S Aisen; Chester Mathis; William E Klunk; karen duff
An Abeta sequestration approach using non-antibody Abeta binding agents.
Current Alzheimer research 2005;2(2):265-8.
2005: Paul S Aisen
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Journal of the American Academy of Nurse Practitioners 2005;Suppl():5-7.
2005: Illana Gozes; Bruce H Morimoto; Jacqueline Tiong; Anthony Fox; Karole Sutherland; David Dangoor; Miriam Holser-Cochav; Karin Vered; Paul Newton; Paul S Aisen; Yasuji Matsuoka; Christopher H van Dyck; Leon J Thal
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
CNS drug reviews 2005;11(4):353-68.
2005: Paul S Aisen
The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.
CNS drugs 2005;19(12):989-96.
2005: Rochelle E Tractenberg; Maxine Weinstein; Myron Weiner; Paul S Aisen; Jong-Ling Fuh; Noreen Goldman; Yi-Li Chuang
Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly.
Neuroepidemiology 2005;24(1-2):110-6.
2004: Sally Walsh; Paul S Aisen
Inflammatory processes and Alzheimer's disease.
Expert review of neurotherapeutics 2004;4(5):793-8.
2004: Yuko Horikoshi; Gaku Sakaguchi; Amanda Becker; Audrey J Gray; karen duff; Paul S Aisen; Haruyasu Yamaguchi; Masahiro Maeda; Noriaki Kinoshita; Yasuji Matsuoka
Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant.
Biochemical and biophysical research communications 2004;319(3):733-7.
2004: Pamela A. Saunders; Paul S Aisen
Georgetown University School of Medicine.
Academic medicine : journal of the Association of American Medical Colleges 2004;79(7 Suppl):S45-50.
2004: Michael Grundman; Ronald C. Petersen; Steven H Ferris; Ronald Thomas; Paul S Aisen; David A Bennett; Norman L Foster; Clifford R Jack; Douglas Galasko; Rachelle S Doody; Jeffrey A Kaye; Mary Sano; Richard C Mohs; S Gauthier; Hyun T Kim; Shelia Jin; Arlan N Schultz; Kimberly Schafer; Ruth Mulnard; Christopher H van Dyck; Jacobo E Mintzer; Edward Zamrini; Deborah A Cahn-Weiner; Leon J Thal
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
Archives of neurology 2004;61(1):59-66.
2003: W A van Gool; Paul S Aisen; Piet Eikelenboom
Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?
Journal of neurology 2003;250(7):788-92.
2003: Paul S Aisen; Kimberly Schafer; Michael Grundman; Eric Pfeiffer; Mary Sano; Kenneth L Davis; Martin R Farlow; Shelia Jin; Ronald Thomas; Leon J Thal
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2003;289(21):2819-26.
2003: Paul S Aisen; Kimberly Schafer; Michael Grundman; Ronald Thomas; Leon J Thal
NSAIDs and hypertension.
Archives of internal medicine 2003;163(9):1115; author reply 1115-6.
2003: Paul S Aisen; Susan Egelko; Howard Andrews; Ramon Diaz-Arrastia; Myron Weiner; Charles DeCarli; William J Jagust; Joshua Miller; Ralph Green; Karen Bell; Mary Sano
A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2003;11(2):246-9.
2003: Pankaj D Mehta; Bruce A Patrick; Tuula Pirttila; Patricia K Coyle; Paul S Aisen
Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid.
Journal of clinical laboratory analysis 2003;17(1):18-21.
2003: Paul S Aisen; JD Berg; Suzanne Craft; Elaine Peskind; Mary Sano; Linda Teri; Ruth Mulnard; Ronald Thomas; Leon J Thal
Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition.
Psychoneuroendocrinology 2003;28(1):113-20.
2002: Paul S Aisen
The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease.
Lancet neurology 2002;1(5):279-84.
2002: Paul S Aisen
Anti-inflammatory agents in Alzheimer's disease.
Current neurology and neuroscience reports 2002;2(5):405-9.
2002: Zhongmin Xiang; Lap Ho; Jennifer Valdellon; David R Borchelt; Kevin Kelley; Lauren Spielman; Paul S Aisen; Giulio Maria Pasinetti
Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology.
Neurobiology of aging 2002;23(3):327-34.
2002: Paul S Aisen; J Schmeidler; Giulio Maria Pasinetti
Randomized pilot study of nimesulide treatment in Alzheimer's disease.
Neurology 2002;58(7):1050-4.
2002: Paul S Aisen
Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease.
Journal of pain and symptom management 2002;23(4 Suppl):S35-40.
2002: Lauren Spielman; David Winger; Lap Ho; Paul S Aisen; Esther Shohami; Giulio Maria Pasinetti
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2.
Acta neuropathologica 2002;103(2):157-62.
2001: Paul S Aisen; Deborah B Marin; Adam Brickman; J Santoro; M Fusco
Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease.
Alzheimer disease and associated disorders 2001;15(2):96-101.
2001: Lap Ho; Dushyant P Purohit; Vahram Haroutunian; JD Luterman; F Willis; J Naslund; Joseph Buxbaum; Richard C Mohs; Paul S Aisen; Giulio Maria Pasinetti
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.
Archives of neurology 2001;58(3):487-92.
2001: Lap Ho; Y Guo; Lauren Spielman; O Petrescu; Vahram Haroutunian; Dushyant P Purohit; A Czernik; Shrishailam Yemul; Paul S Aisen; Richard C Mohs; Giulio Maria Pasinetti
Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique.
Neuroscience letters 2001;298(3):191-4.
2001: P Mukherjee; C Rachita; Paul S Aisen; Giulio Maria Pasinetti
Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death.
Clinical and experimental rheumatology 2001;19(1 Suppl 22):S7-11.
2000: M Hull; Giulio Maria Pasinetti; Paul S Aisen
Elevated plasma neopterin levels in Alzheimer disease.
Alzheimer disease and associated disorders 2000;14(4):228-30.
2000: JD Luterman; Vahram Haroutunian; Shrishailam Yemul; Lap Ho; Dushyant P Purohit; Paul S Aisen; Richard C Mohs; Giulio Maria Pasinetti
Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia.
Archives of neurology 2000;57(8):1153-60.
2000: Lap Ho; JD Luterman; Paul S Aisen; Giulio Maria Pasinetti; Thomas J Montine; J D Morrow
Elevated CSF prostaglandin E2 levels in patients with probable AD.
Neurology 2000;55(2):323.
2000: Paul S Aisen
Anti-inflammatory therapy for Alzheimer's disease.
Neurobiology of aging 2000;21(3):447-8; discussion 451-3.
2000: Paul S Aisen; Kenneth L Davis; JD Berg; Kimberly Schafer; K Campbell; Ronald Thomas; Myron Weiner; Martin R Farlow; Mary Sano; Michael Grundman; Leon J Thal
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.
Neurology 2000;54(3):588-93.
2000: Paul S Aisen
Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial.
Acta neurologica Scandinavica. Supplementum 2000;176():85-9.
2000: Pankaj D Mehta; Tuula Pirttilä; Sangita P Mehta; Eugene A Sersen; Paul S Aisen; Henryk M Wisniewski
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Archives of neurology 2000;57(1):100-5.
1999: Pankaj D Mehta; Bruce A Patrick; Arthur J Dalton; Paul S Aisen; M E Emmerling; Eugene A Sersen; Henryk M Wisniewski
Increased levels of tau-like protein in patients with Down syndrome.
Neuroscience letters 1999;275(3):159-62.
1999: Kevin A Kelley; Lap Ho; David Winger; J Freire-Moar; C B Borelli; Paul S Aisen; Giulio Maria Pasinetti
Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2.
The American journal of pathology 1999;155(3):995-1004.
1999: Lap Ho; C Pieroni; David Winger; Dushyant P Purohit; Paul S Aisen; Giulio Maria Pasinetti
Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease.
Journal of neuroscience research 1999;57(3):295-303.
1999: H Osaka; P Mukherjee; Paul S Aisen; Giulio Maria Pasinetti
Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity.
Journal of cellular biochemistry 1999;73(3):303-11.
1998: Paul S Aisen; Alyssa C Luddy; Martina Durner; J F Reinhard; Giulio Maria Pasinetti
HLA-DR4 influences glial activity in Alzheimer's disease hippocampus.
Journal of the neurological sciences 1998;161(1):66-9.
1998: Giulio Maria Pasinetti; Paul S Aisen
Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.
Neuroscience 1998;87(2):319-24.
1998: Lap Ho; H Osaka; Paul S Aisen; Giulio Maria Pasinetti
Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death.
Journal of neuroimmunology 1998;89(1-2):142-9.
1998: SM Gabriel; Deborah B Marin; Paul S Aisen; Melinda Lantz; LD Altstiel; Kenneth L Davis; Richard C Mohs
Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old.
The American journal of psychiatry 1998;155(5):698-700.
1998: Paul S Aisen; Giulio Maria Pasinetti
Glucocorticoids in Alzheimer's disease. The story so far.
Drugs & aging 1998;12(1):1-6.
1997: Paul S Aisen; Kenneth L Davis
The search for disease-modifying treatment for Alzheimer's disease.
Neurology 1997;48(5 Suppl 6):S35-41.
1997: Georges Tocco; J Freire-Moar; Steven S. Schreiber; SH Sakhi; Paul S Aisen; Giulio Maria Pasinetti
Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.
Experimental neurology 1997;144(2):339-49.
1997: Brian A Lawlor; Paul S Aisen; C Green; E Fine; J Schmeïdler
Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
International journal of geriatric psychiatry 1997;12(3):319-22.
1997: Paul S Aisen
Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies.
Gerontology 1997;43(1-2):143-9.
1996: Paul S Aisen; Deborah B Marin; L Altstiel; C Goodwin; B Baruch; R Jacobson; T Ryan; Kenneth L Davis
A pilot study of prednisone in Alzheimer's disease.
Dementia (Basel, Switzerland) 1996;7(4):201-6.
1996: M O Fagarasan; Paul S Aisen
IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells.
Brain research 1996;723(1-2):231-4.
1996: Paul S Aisen
Inflammation and Alzheimer disease.
Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid 1996;28(1-3):83-8.
1995: Mindy Aisen; Paul S Aisen
Antinuclear antibodies in multiple sclerosis.
Neurology 1995;45(12):2299-300;author reply 2300-1.
1995: Mindy Aisen; J Stallman; Paul S Aisen
The sympathetic skin response in the shoulder-hand syndrome complicating tetraplegia.
Paraplegia 1995;33(10):602-5.
1994: Mindy Aisen; D Iverson; C Schwalbe; B Weaver; Paul S Aisen
Falls on a neurorehabilitation unit: reassessment of a prevention program.
The Journal of the American Paraplegia Society 1994;17(4):179-82.
1994: L M Bierer; Paul S Aisen; Michael Davidson; T M Ryan; James Schmeidler; Kenneth L Davis
A pilot study of clonidine plus physostigmine in Alzheimer's disease.
Dementia (Basel, Switzerland) 1994;5(5):243-6.
1994: Paul S Aisen; Mindy Aisen
Shoulder-hand syndrome in cervical spinal cord injury.
Paraplegia 1994;32(9):588-92.
1994: Paul S Aisen; Kenneth L Davis
Inflammatory mechanisms in Alzheimer's disease: implications for therapy.
The American journal of psychiatry 1994;151(8):1105-13.
1993: J S Stallman; Paul S Aisen; Mindy Aisen
Pulmonary embolism presenting as fever in spinal cord injury patients: report of two cases and review of the literature.
The Journal of the American Paraplegia Society 1993;16(3):157-9.
1993: L M Bierer; Paul S Aisen; Michael Davidson; T M Ryan; R G Stern; James Schmeidler; Kenneth L Davis
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
Alzheimer disease and associated disorders 1993;7(2):98-104.
1992: Paul S Aisen; Brian A Lawlor
Neuroleptic malignant syndrome induced by low-dose haloperidol.
The American journal of psychiatry 1992;149(6):844.
1992: Paul S Aisen; Brian A Lawlor
GPSYCH: Clinical management software for a Geropsychiatry Division.
Proceedings / the ... Annual Symposium on Computer Application [sic] in Medical Care. Symposium on Computer Applications in Medical Care 1992;():322-6.
1991: Paul S Aisen
Medical evaluation of the elderly psychiatric patient.
The Mount Sinai journal of medicine, New York 1991;58(1):85-90.
1989: Elisse Kramer; Blaine Greenwald; Paul S Aisen; C Brod-Miller
Hypochondriasis in the elderly depressed.
Journal of the American Geriatrics Society 1989;37(6):507-10.
1988: N K Pervez; Paul S Aisen; Ira J Bleiweiss; B Brady; S Winters
Occult aspiration of a nut in an elderly patient: a case report.
The American journal of forensic medicine and pathology 1988;9(2):163-5.
1985: Paul S Aisen; K A Haines; W Given; S B Abramson; M Pras; C Serhan; Mats Hamberg; Bengt Samuelsson; Gerald Weissmann
Circulating hydroxy fatty acids in familial Mediterranean fever.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(4):1232-6.
1983: Paul S Aisen; Bruce N Cronstein; S B Kramer
Systemic lupus erythematosus in a patient with Reiter's syndrome.
Arthritis and rheumatism 1983;26(11):1405-8.